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ABSTRACT The gold standard for severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection diagnosis is reverse transcription (RT)-PCR from a nasopharyn-
geal swab specimen (NPS). Its collection involves close contact between patients and
health care workers, requiring a significant amount of workforce and putting them
at risk of infection. We evaluated self-collection of alternative specimens and com-
pared their sensitivity and cycle threshold (CT) values to those of NPS. We visited
acute coronavirus disease 2019 (COVID-19) outpatients to collect concomitant NPS
and gargle specimens and had patients self-collect gargle and either sputum or spit
specimens the next morning. We included 40 patients and collected 40 concomitant
NPS and gargle specimens, as well as 40 gargle, 22 spit, and 16 sputum specimens
the next day (2 patients could not produce sputum). All specimens were as sensitive
as NPS. Gargle specimens had a sensitivity of 0.97 (95% confidence interval [CI], 0.92
to 1.00), whether collected concomitantly with NPS or the next morning. Next-morn-
ing spit and sputum specimens showed sensitivities of 1.00 (95% CI, 1.00 to 1.00)
and 0.94 (95% CI, 0.87 to 1.00]), respectively. The gargle specimens had significantly
higher mean CT values of 29.89 (standard deviation [SD], 4.63; P , 0.001) and 29.25
(SD, 3.99; P , 0.001) when collected concomitantly and the next morning, respec-
tively, compared to NPS (22.07 [SD, 4.63]). CT values obtained with spit (23.51 [SD,
4.57]; P = 0.11) and sputum (25.82 [SD, 9.21]; P = 0.28) specimens were close to
those of NPS. All alternative specimen collection methods were as sensitive as NPS,
but spit collection appeared more promising, with a low CT value and ease of collec-
tion. Our findings warrant further investigation.
IMPORTANCE Control of the COVID-19 pandemic relies heavily on a test-trace-isolate
strategy. The most commonly used specimen for diagnosis of SARS-CoV-2 infection
is a nasopharyngeal swab. However, this method is quite uncomfortable for the
patient, requires specific equipment (nose swabs and containers), and requires close
proximity to health care workers, putting them at risk of infection. Developing alter-
native sampling strategies could decrease the burden for health care workers, help
overcome potential shortages of equipment, and improve acceptability of testing by
reducing patient discomfort.
KEYWORDS alternative testing methods, COVID-19, gargle, nasopharyngeal swab,
SARS-CoV-2, spit, sputum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection controlrelies on a test-trace-isolate strategy with early diagnosis and isolation of infected
individuals followed by identification of contacts (1). It has led to an initial shortage of
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personal protective and sampling equipment, as well as increasing the workload of
health care workers (HCWs) (2, 3). In Finland alone (approximately 5,500,000 inhabi-
tants), by 20 March 2021 over 3,700,000 tests had been conducted and analyzed
nationwide since the start of the coronavirus disease 2019 (COVID-19) pandemic (4, 5),
including 145,000 tests in the first week of March 2021.
Collection of a nasopharyngeal swab specimen (NPS) is the gold standard for SARS-
CoV-2 infection diagnosis (6). It is an unpleasant procedure, requiring close contact
with a HCW and increasing the HCW’s risk of infection (2, 7). The use of an alternative
specimen collection method could increase testing capacities, as well as decreasing
HCWs’ workload and risk of infection (7). There have been several studies evaluating al-
ternative specimen collection methods, but none of the specimen collection methods
has yet superseded NPS collection (3, 8–10), even though one Finnish private health
care provider now offers asymptomatic patients the possibility to self-collect a gargle
specimen as an alternative to NPS collection (11). We evaluated and compared three
alternative specimen collection methods that would not require close contact with a
HCW and compared their sensitivity and cycle threshold (CT) values with those for NPS.
RESULTS
We enrolled 40 patients, with a mean age of 38.7 years (standard deviation [SD],
12.6 years), including 21 female patients (53%). Enrollment was performed as soon as
the patients received the positive testing results, either 1 day (n = 27/40 [67.5%]) or 2
days (n = 13/40 [32.5%]) after they had been sampled by NPS for COVID-19 diagnosis
(Fig. 1). Thirty-one patients had been symptomatic since disease onset (see Table S1 in
the supplemental material), with most prevalent symptoms being fatigue (86%), head-
ache (81%), and cough (79%). At the time of specimen collection, only 24 patients
were symptomatic, with the most prevalent symptoms being cough (44%), anosmia
(42%), and headache (40%).
We collected 40 concomitant NPS and gargle specimens on the recruitment day, as
well as 40 next-morning gargle specimens. Of 22 patients assigned to the spit speci-
men collection group, all of them gave back specimens; of 18 patients assigned to the
sputum group, 2 patients could not produce sputum, and thus only 16 sputum sam-
ples were included in the analysis.
All specimens were generally as sensitive as NPS to diagnose SARS-CoV-2 infection.
The morning spit specimens showed the highest sensitivity (sensitivity, 1.00 [95% con-
fidence interval [CI], 1.00 to 1.00]), followed by gargle specimens, regardless of when
they had been collected (0.97 [95% CI, 0.92 to 1,00]). The sputum specimens had the
lowest sensitivity (0.94 [95% CI, 0.87 to 1.00]) (Table 1).
FIG 1 Timeline of the study.
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We compared CT values obtained from alternative specimens to NPS (Table 2). NPS
had the lowest CT value (22.07; SD, 4.63), although it was not significantly lower than
values for sputum (25.82 [SD, 9.21]; P = 0.28) and spit (23.51 [SD, 4.57]; P = 0.11) speci-
mens. Both gargle specimens had statistically significantly higher CT values, compared
to NPS (Table 2). All patients’ different specimen results are presented in Fig. 2.
DISCUSSION
We evaluated self-collection of alternative specimens, i.e., gargle, spit, and sputum
specimens, and compared their sensitivity and CT values to those for NPS for SARS-
CoV-2 infection diagnosis. All specimen collection methods were comparably sensitive
as NPS, with sensitivities exceeding 90%. Compared to NPS, gargle specimens had sig-
nificantly higher CT values, likely due to dilution by gargling water, while spit and spu-
tum specimens collected on the following day had higher, although not significantly
different, CT values. Additionally, sputum samples appeared more challenging to col-
lect among patients with milder symptoms. Therefore, spit would be the most suitable
alternative specimen to NPS for SARS-CoV-2 infection diagnosis.
Since the beginning of the COVID-19 pandemic, several studies or meta-analyses
have investigated the potential use of saliva specimens for SARS-CoV-2 infection diagnosis
FIG 2 CT values depending on specimen type and time of collection.
TABLE 2 Comparison of CT values obtained with alternative samples versus NPS
Sample type No. of samples CT (mean± SD) Pa
NPS 40 22.076 4.63 Reference
Gargle 1 40 29.896 4.34 ,0.001
Gargle 2 40 29.256 3.99 ,0.001
Sputum 16 25.826 9.21 0.28
Spit 22 23.516 4.57 0.11
aPaired t test.
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among both symptomatic (2, 7, 8, 12–17) and asymptomatic (2, 7, 8, 12–14, 17, 18)
patients. The European Centre for Disease Prevention and Control (ECDC) and the
Centers for Disease Control and Prevention (CDC) have approved the use of saliva or spu-
tum samples as diagnostic specimens for COVID-19 testing for patients with a productive
cough (19, 20).
There have been mixed results, considering differences in CT values between NPS
and saliva specimens (8, 15, 16, 18). These inconclusive results can be caused by vari-
ous factors; morning saliva samples might have higher viral loads, compared to those
from the rest of the day (14), and levels of SARS-CoV-2 in saliva samples correlate with
COVID-19 symptom severity (21). Additionally, the early-morning posterior oropharyn-
geal spitting technique has been considered to have higher sensitivity for SARS-CoV-2
infection diagnosis, compared to NPS (7).
Previously, gargle specimens were also estimated to be sensitive for SARS-CoV-2
infection diagnosis, compared to NPS, including 50 inpatients (22) and outpatients (3,
23) with confirmed COVID-19. CT values for gargle specimens were higher than those
for NPS in those three studies, including one with 19,620 outpatients that is in line
with findings in our study (3, 22, 23). Interestingly, Goldfarb et al., when analyzing 40
COVID-19 outpatients, concluded that gargle specimens had higher sensitivity than sa-
liva specimens (97.5% [95% CI, 86.8 to 99.9%], compared to 78.8% [95% CI, 61.0 to
91.0%]), which is inconsistent with our results. One possible explanation for this could
be that patients were instructed to gargle for a longer time in this study (3). Levican-
Asenjo et al. and Malcynski et al. showed that diagnostic results and CT values were
comparable between sputum specimen and NPS tests during the first 10 days after
COVID-19 diagnosis (24, 25). Our results were also consistent with that study.
The main benefit of alternative specimen collection would be to avoid close contact
with a HCW and to avoid an unpleasant procedure. Overall, it would also increase the
willingness to apply for SARS-CoV-2 testing and the allocation of current resources for
HCWs. However, other practicalities must be considered in developing an alternative
sample collection method. Morning spit collection before any food or water intake
appears to show the best performance but could not be offered in all situations
(appointment for sampling at a later time of day, for example). However, offering this
alternative to self-quarantine patients feeling unwell could be a suitable use of the
morning spit collection method, assuming that the risk of slightly delayed contact trac-
ing did not outweigh the decreased risk of exposure for HCWs.
The main limitations of our work were small sample size (40 participants in total)
and the fact that we did not analyze whether delayed transport or extended storage
before analysis could possibly hamper sensitivity; all samples were transported and
processed on the same day. Furthermore, the volume and timing of samples (e.g., the
second gargle sample after fluid intake) had some variation, which could have an effect
on the analysis. Additionally, because the study sample consisted of participants with
recent positive results, most patients still tested positive with most methods, meaning
that the values obtained regarding specificity should be interpreted with caution.
However, we conducted this study as an exploratory assessment of alternative speci-
men collection methods and focused on patients with the most common clinical pic-
ture of COVID-19, with mild symptoms, because they are the ones who would most
benefit from noninvasive alternative specimen collection. In addition, we managed to
collect all samples within 1 to 2 days after diagnosis, while patients were still in the
acute phase of the disease.
CONCLUSION
Among gargle, spit, and sputum specimens, morning collection of spit before any
food or water intake or teeth brushing appeared to be the most suitable alternative
specimen collection method, with CT values as low as those obtained with NPS and
with ease of collection for patients with mild symptoms. Our findings are promising
but warrant further investigations with larger study populations. It is important to note
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that the efficiency of different RNA extraction methods can significantly vary among
sample materials. For this reason, before changing sample materials, the detection
method used must be carefully validated. We will consider offering to patients with
mild symptoms who are seeking diagnosis in a pilot testing center the possibility of
enrolling in a study assessing whether, in the general population, spit collected on the
next morning has the same performance as in our exploratory sample. If so, in the long
run, we could offer patients with mild symptoms the choice between at-home self-col-
lection of spit and NPS collection at a testing center. This would not only decrease dis-
comfort but also decrease HCWs’ exposure and burden.
MATERIALS ANDMETHODS
Sample collection. We contacted confirmed COVID-19 outpatients who had been diagnosed with
SARS-CoV-2 infection by reverse transcription (RT)-PCR using NPS a few days earlier. Children ,2 years
of age were not eligible for participation. After calling the patients for recruitment, we visited them on
the same day and the following day.
During the first home visit, we gathered informed consent, gave participants a link to an online
symptom questionnaire, and collected a NPS and a gargle specimen (gargle 1). We also gave them
instructions (see Appendix S1 in the supplemental material) and containers for collection of gargle (gar-
gle 2) and, depending on the recruitment week, sputum or spit specimens the next morning. On the
day following the first visit, the patients themselves collected the second gargle (gargle 2) and spit or
sputum specimens. We retrieved the self-collected samples later in the day. The timeline of the study is
presented in Fig. 1.
All alternative specimens were collected into a 70-ml plastic container. To collect the gargle speci-
mens, the patients were instructed to have a sip of water and gargle it for 5 to 20 s before spitting it in
the container. For spit collection, the patients had to spit continuously into the container until they filled
one-half its volume; for the sputum specimens, the patients were asked to cough sputum from deep in
their lungs and then spit it into the container. Both the spit and sputum specimens were to be collected
in the morning before the patients ate, drank, or brushed their teeth, whereas the gargle sample was
collected by the participants later in the morning. All specimens were transported at room temperature
and analyzed on the same day in the Expert Microbiology Unit at the Finnish Institute for Health and
Welfare (THL). The Finnish communicable diseases law and the law on the duties of the THL allowed the
implementation of this noninvasive research without seeking further ethical approval (26).
Laboratory methods. RNA extraction from samples was performed using the Chemagic Viral300
DNA/RNA kit H96 (PerkinElmer) according to the manufacturer’s instructions. A sample volume of 300 ml
and an elution volume of 50 ml were used. Highly viscose gargle samples were vortex-mixed with 1 ml
phosphate-buffered saline (PBS) before 300 ml was taken for RNA extraction. Real-time RT-PCR was per-
formed using qScript XLT one-step RT-quantitative PCR (qPCR) ToughMix (Quantabio). SARS-CoV-2 was
detected using the E (envelope) gene real-time RT-PCR assay. Primers and probes were based on the
Corman E gene primer/probe set (27). The thermal profile for PCR was 55°C for 20 min and 95°C for
3 min, followed by 45 cycles of 95°C for 15 s and 58°C for 1 min, using a CFX thermal cycler (Bio-Rad).
Statistical analysis. We used NPS RT-PCR test results as the reference and CT values as surrogates
for viral load analysis. We used paired t tests to compare the measured CT values between NPS and gar-
gle specimens and between NPS and sputum/spit specimens. Standard methods were used to calculate
sensitivity and specificity of the other diagnostic tests (index tests) from saliva and sputum/spit speci-
mens. We used McNemar’s exact test to assess the differences in sensitivity and specificity.
We calculated Cohen’s kappa coefficient to evaluate the agreement between the reference and the
index tests. The area under the receiver operating characteristic curve (AUC) and 95% CI were reported.
Because of the imperfect reference test, latent class analysis was used as a correction method to adjust
the estimated sensitivity and specificity of the index tests based on the existing sensitivity and specificity
of the reference test. Model selection was based on the Bayesian information criterion (BIC). Data analy-
sis was performed using R software (version. 3.6.0).
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 0.4 MB.
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